心血管指南

订阅

MedSci主页 / 所有栏目 / 心血管指南

ESC 冠状动脉病理生理学和微循环工作组、ESC 血栓形成工作组和急性心血管护理协会 (ACVC) 与欧洲心律协会 (EHRA) 合作的共识文件：心血管疾病和 COVID-19

2021-12-01 欧洲心律学会 Cardiovascular Research

心血管冠状病毒病

心血管系统在冠状病毒病 19 (COVID-19) 中受到显着影响。

中文标题：

ESC 冠状动脉病理生理学和微循环工作组、ESC 血栓形成工作组和急性心血管护理协会 (ACVC) 与欧洲心律协会 (EHRA) 合作的共识文件：心血管疾病和 COVID-19

英文标题：

ESC 冠状动脉病理生理学和微循环工作组、ESC 血栓形成工作组和急性心血管护理协会 (ACVC) 与欧洲心律协会 (EHRA) 合作的共识文件

发布机构：

欧洲心律学会

发布日期：

2021-12-01

简要介绍：

心血管系统在冠状病毒病 19 (COVID-19) 中受到显着影响。由病毒感染或与强烈的全身炎症和免疫反应间接相关的微血管损伤、内皮功能障碍和血栓形成是重症 COVID-19 的特征。预先存在的心血管疾病和病毒载量与心肌损伤和更糟的结果有关。对细胞因子产生的血管反应以及严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 与血管紧张素转换酶 2 受体之间的相互作用可能导致心脏收缩力显着降低和随后的心肌功能障碍。此外，在没有可检测到的病毒感染的情况下，相当一部分感染了 SARS-CoV-2 的患者并未完全康复，并继续出现大量症状和急性后并发症。这种通常被称为“急性 COVID-19 后”的情况可能有多种原因。病毒库或病毒 RNA 或蛋白质的残留片段会导致这种情况。对 COVID-19 的全身炎症反应有可能增加心肌纤维化，进而可能损害心脏重构。在这里，我们总结了当前对心血管损伤和 COVID-19 急性后后遗症的了解。随着大流行的继续和新的变种出现，只有将我们对病理生理学的理解与相应的临床发现相结合，我们才能提高对潜在机制的了解。识别心血管并发症的新生物标志物以及开发 COVID-19 感染的有效治疗方法至关重要。

相关资料下载：
[AttachmentFileName(sort=1, fileName=ESC 冠状动脉病理生理学和微循环工作组、ESC 血栓形成工作组和急性心血管护理协会 (ACVC) 与欧洲心律协会 (EHRA) 合作的共识文件：心血管疾病和 COVID-19.pdf)] GetToolGuiderByIdResponse(projectId=1, id=0b07f1c00230855e, title=ESC 冠状动脉病理生理学和微循环工作组、ESC 血栓形成工作组和急性心血管护理协会 (ACVC) 与欧洲心律协会 (EHRA) 合作的共识文件：心血管疾病和 COVID-19, enTitle=ESC 冠状动脉病理生理学和微循环工作组、ESC 血栓形成工作组和急性心血管护理协会 (ACVC) 与欧洲心律协会 (EHRA) 合作的共识文件, guiderFrom=Cardiovascular Research, authorId=0, author=, summary=心血管系统在冠状病毒病 19 (COVID-19) 中受到显着影响。, cover=https://img.medsci.cn/20211229/1640758356310_5579292.png, journalId=0, articlesId=null, associationId=206, associationName=欧洲心律学会, associationIntro=欧洲心律学会（EHRAE,uropean Heart Rhythm Association)是欧洲心脏病学会的分支，致力于心律失常的预防与管理，以减少心律失常对患者的影响,减少心源性猝死。官方杂志《欧洲心律失常杂志》影响因子为1.839, copyright=0, guiderPublishedTime=Wed Dec 01 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #2a2a2a;">心血管系统在冠状病毒病 19 (COVID-19) 中受到显着影响。</span><span style="color: #2a2a2a;">由病毒感染或与强烈的全身炎症和免疫反应间接相关的微血管损伤、内皮功能障碍和血栓形成是重症 COVID-19 的特征。</span><span style="color: #2a2a2a;">预先存在的心血管疾病和病毒载量与心肌损伤和更糟的结果有关。</span><span style="color: #2a2a2a;">对细胞因子产生的血管反应以及严重急性呼吸综合征冠状病毒-2 (SARS-CoV-2) 与血管紧张素转换酶 2 受体之间的相互作用可能导致心脏收缩力显着降低和随后的心肌功能障碍。</span><span style="color: #2a2a2a;">此外，</span><span style="color: #2a2a2a;">在没有可检测到的病毒感染的情况下，相当一部分感染了 SARS-CoV-2 的患者并未完全康复，并继续出现大量症状和急性后并发症。</span><span style="color: #2a2a2a;">这种通常被称为&ldquo;急性 COVID-19 后&rdquo;的情况可能有多种原因。</span><span style="color: #2a2a2a;">病毒库或病毒 RNA 或蛋白质的残留片段会导致这种情况。</span><span style="color: #2a2a2a;">对 COVID-19 的全身炎症反应有可能增加心肌纤维化，进而可能损害心脏重构。</span><span style="color: #2a2a2a;">在这里，我们总结了当前对心血管损伤和 COVID-19 急性后后遗症的了解。</span><span style="color: #2a2a2a;">随着大流行的继续和新的变种出现，</span><span style="color: #2a2a2a;">只有将我们对病理生理学的理解与相应的临床发现相结合，我们才能提高对潜在机制的了解。</span><span style="color: #2a2a2a;">识别心血管并发症的新生物标志物以及开发 COVID-19 感染的有效治疗方法至关重要。</span></p>, tagList=[TagDto(tagId=266, tagName=心血管), TagDto(tagId=114466, tagName=冠状病毒病)], categoryList=[CategoryDto(categoryId=2, categoryName=心血管, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=99632, guiderKeyword=Covid-19, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=2, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=1766, appHits=75, showAppHits=0, pcHits=162, showPcHits=1691, likes=1, shares=3, comments=5, approvalStatus=1, publishedTime=Wed Dec 29 14:09:39 CST 2021, publishedTimeString=2021-12-01, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=FUNNYMAN, createdTime=Wed Dec 29 14:14:18 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Fri Jan 05 07:21:33 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=ESC 冠状动脉病理生理学和微循环工作组、ESC 血栓形成工作组和急性心血管护理协会 (ACVC) 与欧洲心律协会 (EHRA) 合作的共识文件：心血管疾病和 COVID-19.pdf)])
ESC 冠状动脉病理生理学和微循环工作组、ESC 血栓形成工作组和急性心血管护理协会 (ACVC) 与欧洲心律协会 (EHRA) 合作的共识文件：心血管疾病和 COVID-19.pdf
下载请点击：
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1085806, encodeId=1afa1085806a9, content=正在学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66c6431032, createdName=ms2000000497830136, createdTime=Thu Dec 30 13:26:20 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085674, encodeId=763410856e467, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Dec 30 06:55:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085512, encodeId=7176108551222, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:20 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085511, encodeId=3d5410855119e, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:17 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085510, encodeId=16e3108551062, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:15 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-30 ms2000000497830136

    正在学习

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1085806, encodeId=1afa1085806a9, content=正在学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66c6431032, createdName=ms2000000497830136, createdTime=Thu Dec 30 13:26:20 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085674, encodeId=763410856e467, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Dec 30 06:55:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085512, encodeId=7176108551222, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:20 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085511, encodeId=3d5410855119e, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:17 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085510, encodeId=16e3108551062, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:15 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-30 微探

    学习学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1085806, encodeId=1afa1085806a9, content=正在学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66c6431032, createdName=ms2000000497830136, createdTime=Thu Dec 30 13:26:20 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085674, encodeId=763410856e467, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Dec 30 06:55:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085512, encodeId=7176108551222, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:20 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085511, encodeId=3d5410855119e, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:17 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085510, encodeId=16e3108551062, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:15 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-29 一己怀

    谢谢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1085806, encodeId=1afa1085806a9, content=正在学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66c6431032, createdName=ms2000000497830136, createdTime=Thu Dec 30 13:26:20 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085674, encodeId=763410856e467, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Dec 30 06:55:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085512, encodeId=7176108551222, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:20 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085511, encodeId=3d5410855119e, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:17 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085510, encodeId=16e3108551062, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:15 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-29 一己怀

    好东西

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1085806, encodeId=1afa1085806a9, content=正在学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d66c6431032, createdName=ms2000000497830136, createdTime=Thu Dec 30 13:26:20 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085674, encodeId=763410856e467, content=学习学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=555f5538552, createdName=微探, createdTime=Thu Dec 30 06:55:45 CST 2021, time=2021-12-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085512, encodeId=7176108551222, content=谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:20 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085511, encodeId=3d5410855119e, content=好东西, beContent=null, objectType=guider, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:17 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1085510, encodeId=16e3108551062, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Wed Dec 29 17:10:15 CST 2021, time=2021-12-29, status=1, ipAttribution=)]
    2021-12-29 一己怀

    学习了

    0

相关指南

《ACC 2020降低2型糖尿病患者心血管风险新疗法的专家共识》解读

暂未更新 · 2021-11-20

2021 SOGC临床实践指南：更年期和心血管疾病（No.422e）

加拿大妇产科医生协会(SOGC,Society of Obstetricians and Gynaecologists of Canada) · 2021-12-04

2021 ESC指南：临床实践中心血管疾病的预防

欧洲心脏病学会(ESC,European Society of Cardiology) · 2021-08-30

ESC 2021 心血管病预防临床实践指南

欧洲心脏病学会(ESC,European Society of Cardiology) · 2021-08-30

2021 年 PACES 儿科患者心血管植入式电子设备的适应症和管理专家共识声明

美国儿科和先天性电生理协会(PACES,Pediatric and Congenital Electrophysiology Society) · 2021-08-01

2021 年 PACES 关于儿科患者心血管植入式电子设备的适应症和管理的专家共识声明：执行摘要

美国儿科和先天性电生理协会(PACES,Pediatric and Congenital Electrophysiology Society) · 2021-08-02

拓展阅读

2019冠状病毒病(COVID-19)疫情防控期间妇科急诊患者临床诊疗防护原则和措施的建议

暂未更新 · 2020-02-18

COVID-19感染患者的气管切开术共识：西班牙

西班牙重症监护医学与冠心病小组学会(SEMICYUC,Spanish Society of Intensive Care Medicine and Coronary Units) · 2020-06-01

OVID-19大流行期间妇科恶性肿瘤的放射治疗：国际专家共识建议

暂未更新 · 2020-06-23

在COVID-19大流行期间接受治疗性放疗的肺癌患者管理共识

暂未更新 · 2020-09-01

肺癌和COVID-19大流行：巴西胸部肿瘤小组的建议

巴西胸部肿瘤组织（Brazilian Thoracic Oncology Group） · 2020-09-01

COVID-19患者的化学预防，诊断，治疗和出院管理：循证临床实践指南（更新版本）

中国医院协会(CHA,Chinese Hospital Association) ·